Background {#Sec1}
==========

Postherpetic neuralgia (PHN), a painful complication of herpes zoster (HZ) or shingles, is characterized by the presence of persistent pain 1--6 months following resolution of acute HZ (i.e., after healing of the associated skin rash) \[[@CR1]--[@CR3]\]. The individual lifetime risk for developing HZ and PHN varies slightly by country, but age-specific rates uniformly show that incidences increase sharply after 50 years of age, and that the elderly are most frequently affected. Approximately 8 in 1,000 people aged ≥60 years, and 10.5 in 1,000 people aged ≥80 years are diagnosed with HZ each year \[[@CR4], [@CR5]\]. In patients who have had HZ, PHN develops in approximately 18 % of patients ≥60 years and 30 % of those ≥80 years \[[@CR6]--[@CR8]\]. The prevalence of PHN is only expected to increase over time as the population ages \[[@CR9]\]. According to the 2013 World Population Data Base, 846 million people (8 %) are ≥65 years and 18.5 million (3 %) are ≥75 years \[[@CR10]\]. The World Population projection estimates that, by 2050, 17 % of the population will be ≥65 years and 8 % will be ≥75 years \[[@CR10]\].

In addition to having a higher prevalence of PHN, elderly patients often have chronic co-morbid conditions (e.g., osteoarthritis and rheumatologic disease) \[[@CR11]\], with a prevalence of multimorbidity reported in as many as 93 % of 45--64 year olds and 98 % of those \>65 years \[[@CR12]\]. Individuals with multimorbidity are at increased risk for longer hospitalizations, polypharmacy, and higher healthcare costs. Among community-dwelling individuals, 37 % of men and 36 % of women aged 75--85 years used at least five prescription medications concurrently \[[@CR13]\]. When prescribing pain medication for this elderly population, drug--drug interactions, as well as drug--disease interactions, need to be taken into account. Adverse reactions have indeed been shown to be more common among older adults and to have greater potential for causing harm \[[@CR14], [@CR15]\]. Furthermore, a steady decline of homeostatic mechanisms and function of important organ systems (including hepatic, renal, cardiac, and central nervous system) associated with aging leads to clinically important changes in drug absorption, metabolism, volume of distribution, plasma concentration, and drug bioavailability in the elderly \[[@CR16]\]. Therefore, although pain management in older patients generally follows the same principle as in younger patients, the approach often requires modifications because of co-morbidities and/or physiological changes associated with aging that alter the pharmacodynamics and pharmacokinetics of drugs.

Agents from four therapeutic categories have demonstrated efficacy in clinical trials for relieving the pain associated with PHN. These include tricyclic antidepressants, anticonvulsants, opioids, and topical anesthetics \[[@CR17]\]. The immediate-release formulation of gabapentin, an anticonvulsant, was approved by the US Food and Drug Administration (FDA) for the treatment of PHN in 2002. It needs to be administered three times daily (tid) due to its nonlinear pharmacokinetics \[[@CR18]\], and the rates of dizziness and somnolence are relatively high (28 and 21 %, respectively) \[[@CR19]\], which may contribute to difficulty attaining efficacious and tolerable dosages. In a retrospective database analysis of patients with PHN who took gabapentin tid, only 14 % of patients reached the recommended therapeutic 1,800 mg/day dosage in, on average, 10 weeks \[[@CR20]\].

A gastroretentive formulation of gabapentin (G-GR, Gralise^®^, Depomed Inc., Newark, CA, USA) was subsequently approved for treatment of PHN \[[@CR21]\]. G-GR uses a polymer-based technology that, following oral administration with a meal, causes the tablet to swell to a size that promotes gastric retention \[[@CR22], [@CR23]\]. By being retained in the stomach for up to 10 h, the tablet gradually releases gabapentin, which optimizes absorption by its transporters, located predominantly in the upper small intestine, which permits once-daily dosing and better titration to therapeutic dosages.

Safety and efficacy of this new, once-daily formulation in PHN were evaluated in two placebo-controlled, double-blind, phase III studies \[[@CR24], [@CR25]\]. The two studies included a 2-week titration to 1,800 mg/day, followed by 8 weeks of stable dosing at 1,800 mg/day, and then 1 week of dose tapering. Over 90 % of patients in the G-GR group completed the titration period in both studies \[[@CR26], [@CR27]\]. The initial 11-week, randomized, double-blind, placebo-controlled, multicenter clinical trial compared G-GR administered once daily (1,800 mg with the evening meal), or as an asymmetric dose (1,200 mg PM/600 mg AM, with a meal) with placebo in patients with PHN persisting for at least 3 months following healing of HZ rash \[[@CR24]\]. Compared with placebo, the average daily pain (ADP) score for patients in the G-GR arm decreased more, but the overall changes in the primary endpoint were not statistically significant. This was attributed to a large placebo-response rate, especially among patients whose rash had resolved within less than 6 months prior to study entry (\~20 % of the study population). Given this finding, the subsequent 11-week, phase III study limited eligibility to patients whose PHN had persisted for at least 6 months following healing of the HZ rash, and patients were randomized to receive G-GR (1,800 mg) or matching placebo once daily with the evening meal \[[@CR25]\]. In that study, there was a significantly greater reduction in ADP score from baseline in the G-GR group compared with placebo (*p* = 0.013), from week 1 and throughout the rest of the study \[[@CR20]\].

To gain further insight into the safety, tolerability, and efficacy of G-GR for the treatment of elderly patients with PHN, we analyzed integrated data from the two phase III studies of 1,800 mg G-GR versus placebo taken once daily with dinner by age (\<75 and ≥75 years).

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Data for patients stratified by age (\<75 and ≥75 years) were obtained from two multicenter, randomized, placebo-controlled, phase III PHN studies (study 81-0045, clinicaltrial.gov identifier: NCT00335933 and study 81-0062, clinicaltrial.gov identifier: NCT00636636) that were designed to assess the safety and efficacy of G-GR in patients with PHN. These studies have been previously described in detail \[[@CR24], [@CR25]\]. The study protocols were approved by a central institutional review board and were conducted in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice. To be eligible for inclusion, adult patients with a diagnosis of PHN and an average numeric pain rating scale score of ≥4 were eligible if ≥3 months (study 81-0045) or ≥6 months (study 81-0062) had elapsed since healing of the HZ rash. Patients were excluded if they had previously failed to respond to treatment with gabapentin tid (≥1,200 mg/day) or pregabalin (≥300 mg/day), had experienced dose-limiting adverse events (AEs) with gabapentin tid, or had hypersensitivity to gabapentin. Concomitant medications---tricyclic or selective serotonin reuptake inhibitor antidepressants, acetaminophen (up to 4 g/day); non-steroidal anti-inflammatory drugs (NSAIDs), and aspirin (up to 325 mg/day)---taken at stable doses for ≥30 days prior to screening were allowed only at their stable doses throughout the study to minimize their effect on the G-GR efficacy and safety assessments. Signed, written informed consent was obtained from each patient or their authorized representative prior to study participation. The 138 patients randomized in study 81-0045 to receive G-GR as an asymmetrically divided dose (1,200 mg PM/600 mg AM) were not included in the dataset used for the current analyses.

Study Design {#Sec4}
------------

The two studies shared the same basic design, which included a 1-week baseline period followed by a 2-week titration period, an 8-week stable dose treatment period, and a 1-week dose-tapering period. Doses were increased to a daily dose of 1,800 mg during the 2-week titration period using a set schedule: day 1 = 300 mg; day 2 = 600 mg; days 3--6 = 900 mg; days 7--10 = 1,200 mg; days 11--14 = 1,500 mg; day 15 = 1,800 mg. Patients continued on a stable dose of 1,800 mg/day for an additional 8 weeks, followed by a 1-week dose-tapering period. All doses were taken once daily with the evening meal.

Each morning, from the beginning of baseline to the end of the efficacy treatment period (treatment week 10), patients recorded their pain intensity during the previous 24 h and sleep interference caused by pain in an electronic diary (DiaryPRO, invivodata, Inc., Pittsburgh, PA, USA). For pain intensity, scoring utilized an 11-point numerical rating scale (NRS; where 0 = no pain, 10 = worst possible pain); sleep interference scoring utilized the same 11-point NRS (where 0 = no interference, 10 = worst possible interference). Assessments for the Patient Global Impression of Change (PGIC) and a neurological examination were completed at week 10 or at early termination.

Efficacy Outcomes {#Sec5}
-----------------

Efficacy parameters included the absolute change and percent change in ADP score on the 11-point NRS from baseline to week 10, the proportion of responders (defined as those patients achieving 30 % or more reduction in ADP from baseline to week 10), the proportion of patients categorized as "Much" or "Very much" improved on the PGIC, and the absolute change and percent change in average daily sleep interference score (SIS) on the 11-point NRS from baseline to week 10. The integrated analysis was based on the modified intent-to-treat (mITT) population that consisted of all patients aged \<75 and ≥75 who received any study treatment and had valid baseline efficacy measures.

Safety Outcomes {#Sec6}
---------------

Safety assessments included the incidence of AEs, serious AEs (SAEs), clinical laboratory assessments, vital signs, and the use of concomitant medications. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA; Version 9.0). The number and percentage of patients reporting one or more AEs were categorized by AE preferred term and AE system organ class, and summarized by treatment group. The safety analyses were performed on the population consisting of all patients aged \<75 or ≥75 years who received at least one dose of study drug.

Statistical Methods {#Sec7}
-------------------

Statistical analyses were performed using SAS (Cary, NC, USA) software, version 9.1.3 or higher. Mean percentage changes and mean absolute changes in ADP scores and in average daily SIS from baseline to week 10 were analyzed using an analysis of covariance (ANCOVA) model that included treatment and center factors, and baseline score as covariates. Missing post-treatment scores were imputed using a last-observation-carried-forward (LOCF) approach. The percentage of responders and the percentage of patients feeling "Much" or "Very much" improved were compared between treatment groups using a *z*-test.

Results {#Sec8}
=======

Characteristics of Study Population {#Sec9}
-----------------------------------

A total of 723 patients (531 aged \<75 years \[G-GR = 259; placebo = 272\] and 192 aged ≥75 years \[G-GR = 100; placebo = 92\]) were included in the safety population, and 719 patients (527 aged \<75 years \[G-GR = 256; placebo = 271\] and all patients ≥75 years) were included in the efficacy population. Patient demographics and baseline disease characteristics were largely similar for patients in the two age groups (Table [1](#Tab1){ref-type="table"}). The majority of patients were female and Caucasian. The mean age was 61.5 years for the \<75-year subgroup and 79.3 years for the ≥75-year subgroup. The mean ADP scores at baseline were 6.4 for the \<75-year subgroup and 6.8 for the ≥75-year subgroup. The only significant difference in baseline characteristics between the subgroups was that older patients had reduced renal function. Based on calculated creatinine clearance rates (using the Cockroft--Gault method), patients ≥75 years had a mean (standard deviation \[SD\]) creatinine clearance of 65.4 (13.7) ml/min versus 95.6 (48.0) ml/min for patients \<75 years (Table [1](#Tab1){ref-type="table"}).Table 1Demographics and baseline characteristics, efficacy populationTotal (*n* = 719)\<75 years (*n* = 527)≥75 years (*n* = 192)Age (years), mean (SD)66.2 (12.3)61.5 (10.8)79.3 (3.4) Range21--8921--7475--89Sex, *n* (%) Female411 (57.2)309 (58.6)102 (53.1) Male308 (42.8)218 (41.4)90 (46.9)Race, *n* (%) Caucasian637 (88.6)462 (87.7)175 (91.1) Other82 (11.4)65 (12.3)17 (8.9) Weight (kg), mean (SD)81.2 (17.9)82.4 (18.9)78.1 (14.6)BMI (kg/m^2^), mean (SD)28.8 (5.6)29.1 (5.9)27.9 (4.7)Creatinine clearance^a,b^ (ml/min) Mean (SD)87.5 (44.0)95.6 (48.0)65.4 (13.7) \<80 ml/min, *n* (%)349 (48.5)189 (35.9)160 (83.3) ≥80 ml/min, *n* (%)352 (49.0)322 (61.1)30 (15.6)Average Daily Pain Score Mean (SD)6.5 (1.4)6.4 (1.4)6.8 (1.4) Months since HZ resolution^b^, mean (SD)27.9 (36.0)26.1 (36.9)32.8 (32.8) \<6 months, *n* (%)68 (9.5)54 (10.2)14 (7.3) 6--12 months, *n* (%)197 (27.4)157 (29.8)40 (20.8) \>12 months, *n* (%)449 (62.4)311 (59.0)138 (71.9)Location of neuropathic pain^c^, *n* (%) Face152 (21.1)104 (19.7)48 (25.0) Anterior torso291 (40.5)218 (41.4)73 (38.0) Posterior torso295 (41.0)218 (41.4)77 (40.1) Arms68 (9.5)44 (8.3)24 (12.5) Legs49 (6.8)35 (6.6)14 (7.3) Other150 (20.9)119 (22.6)31 (16.1)^a^Creatinine clearance as calculated by the Cockroft--Gault method^b^Data not available for some patients^c^Patients may be reported in more than one category*BMI* body mass index, *SD* standard deviation, *HZ* herpes zoster

Titration, Adherence, and Study Completion {#Sec10}
------------------------------------------

The majority of patients was titrated to the effective dosage (1,800 mg/day) within 2 weeks and the rates were similar between the age subgroups (94.6 % for \<75 years and 96.0 % for ≥75 years). Most patients completed the study and, when stratified by age, slightly more patients in the older subgroup completed the study (88.0 % for the ≥75-years subgroup and 81.9 % for the \<75-years subgroup). Overall adherence to the treatment regimen was high (placebo 98.5 %, G-GR 99.2 %).

Efficacy {#Sec11}
--------

At week 10, the percent change from baseline in ADP with G-GR was significantly greater for both age groups compared with placebo (Fig. [1](#Fig1){ref-type="fig"}a). For patients aged ≥75 years, the change in ADP was −21.9 % (95 % CI −30.5 to −13.3) for placebo versus −34.2 % (95 % CI −41.7 to −21.9) for G-GR (*p* = 0.0348). For patients \<75 years of age, the change in ADP was −29.9 % (95 % CI −35.2 to −24.6) for placebo versus −38.3 % (95 % CI −43.5 to −33.1) for G-GR (*p* = 0.0079). Compared with placebo, the mean difference in ADP was −7.8 % in favor of G-GR (95 % CI −12.9 to −2.8) (Fig. [1](#Fig1){ref-type="fig"}b). When stratified by age, the mean difference in ADP was similar between patients ≥75 years (difference between G-GR and placebo, −12.3 %; 95 % CI −23.7 to −0.9) and patients \<75 years (difference between G-GR and placebo, −8.4 %; 95 % CI −14.7 to −2.2).Fig. 1Reduction in ADP score at week 10. **a** Percent change from baseline. *p*-Value is for the test of difference in the LS mean percent change from baseline between the two G-GR age groups and their respective placebo based on the ANCOVA model that includes treatment and center factors, and baseline pain score as a covariate. **b** Forest plot for LS mean difference in ADP. *ADP* average daily pain, *ANCOVA* analysis of covariance, *G-GR* gastroretentive gabapentin, *LS* least square

At week 10, significantly more G-GR- than placebo-treated patients in both age subgroups had ≥30 % reduction in ADP (placebo/G-GR): 30.4/52.0 % for ≥75 years and 45.0/54.7 % for \<75 years (Fig. [2](#Fig2){ref-type="fig"}a). More G-GR patients ≥75 years had ≥30 % reduction in ADP in comparison with placebo (difference between G-GR and placebo, 21.6 %; 95 % CI 8.0--35.1; *p* = 0.0025) than patients \<75 years of age (difference between G-GR and placebo, 9.7 %; 95 % CI 1.2--18.2; *p* = 0.0265) (Fig. [2](#Fig2){ref-type="fig"}b).Fig. 2Proportion of patients with at least 30 % reduction in LOCF ADP score at week 10. **a** Percentage of patients. *p*-Value is the test for treatment effect between the two G-GR age groups and their respective placebo based on the *z* test for the difference in proportions between two groups. **b** Forest plot for LS mean difference in ADP responders. *ADP* average daily pain, *G-GR* gastroretentive gabapentin, *LOCF* last observation carried forward, *LS* least square

Compared with placebo, the mean absolute change from baseline in average daily SIS was also significantly improved in patients in the G-GR group: −1.3 versus −2.4 (*p* = 0.0017) for ≥75 years and −1.8 versus −2.7 (*p* \< 0.0001) for \<75 years (Fig. [3](#Fig3){ref-type="fig"}a). As for ADP scores, the mean difference in SIS between G-GR and placebo groups was similar between older and younger patients (≥75 years: difference −1.1, 95 % CI −1.8 to −0.4 vs. \<75 years: difference −0.8, 95 % CI −1.2 to −0.5) (Fig. [3](#Fig3){ref-type="fig"}b).Fig. 3Reduction in average daily SIS. **a** LS mean (SEM) absolute change by age subgroup. *p*-Value is for the test of difference in the LS mean absolute change from baseline between G-GR age groups and their respective placebo groups based on the ANCOVA model that includes treatment and center factors, and baseline pain score as a covariate. **b** Forest plot for LS mean difference in SIS. *ANCOVA* analysis of covariance, *G-GR* gastroretentive gabapentin, *LS* least square, *SEM* standard error of the mean, *SIS* sleep interference score

Similar numbers of patients ≥75 years of age receiving G-GR considered themselves "Much" or "Very much" improved on the PGIC compared with patients \<75 years of age (Fig. [4](#Fig4){ref-type="fig"}). For ≥75 years, 35.0 % of patients treated with G-GR felt "Much" or "Very much" improved in comparison with 20.7 % of patients receiving placebo (difference 14.4 %, 95 % CI 1.9--26.8; *p* = 0.0272). For \<75 years, 44.9 % of patients treated with G-GR considered themselves "Much" or "Very much" improved compared with 33.6 % of patients receiving placebo (difference 11.3 %, 95 % CI 3.1--19.6; *p* = 0.0077).Fig. 4Percentage of patients who reported feeling "Much" or 'Very Much" improved on Patient Global Impression of Change. *p*-Value for the test of treatment effect between G-GR age groups and their respective placebo groups is based on the *z* test for the difference in proportions between two groups. *G-GR* gastroretentive gabapentin

Safety {#Sec12}
------

Similar numbers of patients aged ≥75 years reported at least one AE compared with patients \<75 years, and in both groups, more AEs were reported for the G-GR arm than the placebo arm (placebo/G-GR): ≥75 years (47.8/56.0 %), \<75 years (41.2/53.7 %) (Table [2](#Tab2){ref-type="table"}). In patients ≥75 years, the AEs that occurred most frequently (placebo/G-GR) were dizziness (3.3/12.0 %), nausea (1.0/5.4 %), somnolence (0/5.0 %), diarrhea (2.2/5.0 %), peripheral edema (0/4.0 %), and urinary tract infections (0/3.0 %). In patients \<75 years, these AEs were reported at a similar frequency (placebo/G-GR): dizziness (1.8/10.4 %), nausea (2.9/4.2 %), somnolence (3.7/4.2 %), diarrhea (2.9/2.7 %), peripheral edema (0.4/3.9 %), and urinary tract infections (0.7/1.2 %) (Table [2](#Tab2){ref-type="table"}). The prevalence of all AEs, including the most common for gabapentinoids (dizziness and somnolence), decreased rapidly during the 2-week titration period and reached sustained low levels after approximately 4--5 weeks of treatment (Fig. [5](#Fig5){ref-type="fig"}). For patients aged ≥75 years, study discontinuations due to AEs were more frequent in the G-GR group than in the placebo group (9.0 vs. 5.4 %). For patients aged \<75 years, discontinuation rates due to AEs were lower for G-GR than for placebo (6.3 vs. 10.0 %).Table 2Summary of adverse events, safety populationPreferred term, *n* (%)\<75 years≥75 yearsPlacebo (*n* = 272)G-GR (*n* = 259)Placebo (*n* = 92)G-GR (*n* = 100)Patients with ≥1 AE112 (41.2)139 (53.7)44 (47.8)56 (56.0)≥1 AE leading to study discontinuation26 (10.0)17 (6.3)5 (5.4)9 (9.0)≥1 SAEs8 (2.9)6 (2.3)3 (3.3)2 (2.0)AEs^a^ Dizziness5 (1.8)27 (10.4)3 (3.3)12 (12.0) Nausea8 (2.9)11 (4.2)1 (1.0)5 (5.4) Headache11 (4.0)14 (5.4)4 (4.3)1 (1.0) Somnolence10 (3.7)11 (4.2)05 (5.0) Diarrhea8 (2.9)7 (2.7)2 (2.2)5 (5.0) Edema, peripheral1 (0.4)10 (3.9)04 (4.0) Dry mouth4 (1.5)8 (3.1)1 (1.1)2 (2.0) Urinary tract infection2 (0.7)3 (1.2)03 (3.0) Nasopharyngitis8 (2.9)7 (2.7)1 (1.1)2 (2.0) Weight increased1 (0.4)7 (2.7)1 (1.1)0 Constipation1 (0.4)3 (1.2)02 (2.0) Herpes zoster3 (1.1)2 (0.8)1 (1.1)2 (2.0) Pneumonia01 (0.4)02 (2.0) Pain in extremity1 (0.4)5 (1.9)1 (1.1)2 (2.0) Rash4 (1.5)1 (0.4)02 (2.0) Blood urea increased0002 (2.0) Sedation0002 (2.0)^a^Includes events reported for ≥2 % of patients in any group*AE* adverse event, *G-GR* gastroretentive gabapentin, *SAE* serious adverse eventFig. 5Adverse events over 12 weeks. **a** All adverse events. **b** Dizziness. **c** Somnolence

There was no significant difference between both age subgroups in reporting SAEs (Table [2](#Tab2){ref-type="table"}). For \<75 years, SAEs were experienced by eight (2.9 %) patients in the placebo group and six (2.3 %) patients in the G-GR group. For ≥75 years, three (3.3 %) patients in the placebo group and two (2.0 %) patients in the G-GR group experienced SAEs. None of the SAEs were considered by investigators to be related to study drug. Two deaths occurred in the placebo group (one in each age subgroup), both from myocardial infarction. No clinically significant changes in vital signs, weight, or laboratory parameters were noted.

Discussion {#Sec13}
==========

Elderly patients, who account for the demographic subgroup at highest risk for developing PHN, represent the fastest-growing segment of the population in Western countries \[[@CR9]\]. Although the vaccine (Zostavax^®^, Merck, Whitehouse Station, NJ, USA) effective at preventing HZ and PHN \[[@CR28]\] has been available for patients ≥60 years since 2006, and for patients ≥50 years since 2011 \[[@CR29]\], only approximately 8 % of adults aged ≥60 years reported having had the vaccination by 2011 \[[@CR30]\]. Given that the incidence and prevalence of PHN is expected to increase in the elderly population, and that PHN can be a huge burden and have a significant effect on the quality of life of elderly patients \[[@CR31]\], this is concerning.

Whether vaccinated or not, for elderly patients who develop PHN, co-morbidities and polypharmacy are common and should be taken into account when prescribing medications. Drugs commonly used to treat PHN, including tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors, gabapentin and pregabalin, and opioids, are each associated with AEs that may be especially problematic in frail or vulnerable elderly patients \[[@CR32]\]. Tricyclic antidepressant therapy for PHN in the elderly is generally avoided because it is contraindicated or is poorly tolerated (e.g., excessive sedation, cognitive impairment, constipation, dry mouth, and orthostatic hypotension) \[[@CR33]\]. Opioid analgesics are considered effective as second-line medications, but because the half-life of the active drugs and their metabolites are increased in the elderly, it is recommended that dosages be reduced, dose frequency be reduced, and that creatinine clearance be monitored \[[@CR32], [@CR34]\]. In addition, opioids may be problematic for elderly patients as they cause constipation, cognitive impairment, dizziness, and may lead to an increased risk of hip fracture \[[@CR34], [@CR35]\]. Also, they are more likely to lead to drug--drug interactions in elderly patients who are frequently taking medications (e.g., beta-blockers, statins, selective serotonin reuptake inhibitors, NSAIDs, proton pump inhibitors, and sedative hypnotics) that are metabolized by the same cytochrome P450 (CYP) enzymes \[[@CR36]\]. Gabapentin is an attractive treatment option for older patients due to its low propensity for drug--drug interactions, as it is not metabolized by the CYP system drug-metabolizing enzymes, but absorbed by a saturable [l]{.smallcaps}-amino acid transporter in the upper small intestine and renally excreted \[[@CR37]\]. The fact that gabapentin is excreted by the kidneys and not metabolized also means that physiological changes associated with aging that effect drug absorption, metabolism, volume of distribution, plasma concentration, and drug bioavailability are not an issue for gabapentin, but dosages should be adjusted in patients with renal impairment. However, despite these benefits, for the immediate-release formulation of gabapentin, the tid dosing regimen due to gabapentin's short half-life results in the saturation of [l]{.smallcaps}-amino acid transporters and nonlinear pharmacokinetics, and the rapid rise in gabapentin plasma levels after each dose is associated with a high incidence of common AEs \[[@CR18], [@CR19]\], all of which may be especially bothersome for the elderly. Thus, effective and well tolerated therapy with improved pharmacokinetics, simpler dosing, and reduced AEs with once-daily G-GR may provide a needed therapeutic option for elderly patients with PHN.

Gastroretentive technology used in the formulation of G-GR allows convenient once-daily dosing and for patients to reach the recommended dosage of 1,800 mg/day within 2 weeks \[[@CR21], [@CR23]\]. Upon contact with gastric juices, G-GR tablets immediately begin to swell to 3--4 times their original size and slowly release gabapentin. When taken with meals, the tablets are retained in the stomach for approximately 8--9 h and provide a steady and continuous delivery of gabapentin to its site of absorption. This gradual and steady release of gabapentin reduces the likelihood of the [l]{.smallcaps}-amino acid transporters being saturated, and results in improved pharmacokinetics, better dose proportionality and bioavailability, and consequently simpler dosing and more rapid titration to an effective dosage for G-GR compared with immediate-release gabapentin tid \[[@CR21], [@CR23]\].

In the current analysis of G-GR in patients with PHN, almost all elderly patients ≥75 years (96 %) were able to tolerate the titration schedule and reach the therapeutic dosage of 1,800 mg/day G-GR within 2 weeks. This is in contrast with results obtained from a retrospective analysis of PHN patients treated with gabapentin tid, which showed that only 14 % of patients were able to attain a daily dosage of 1,800 mg and that, for those who did, it took over 2 months \[[@CR20]\]. In addition to the simplified dosing and shorter titration to an efficacious dosage, G-GR showed good efficacy, regardless of patient age or renal function. For elderly patients (≥75 years), treatment with the once-daily G-GR formulation significantly reduced the mean ADP scores to levels similar to those for younger patients when compared with placebo, and which were comparable to those previously observed for the overall study population \[[@CR24]--[@CR27]\]. For a pain decrease that is considered clinically meaningful \[[@CR38]\], more elderly than younger patients (21.6 vs. 9.7 % above placebo) had at least a 30 % reduction in ADP at week 10. Based on the results from the SIS measured on the same NRS widely used to assess pain \[[@CR39]\], elderly patients taking G-GR recorded reductions in SIS similar to those for younger patients. Sleep disturbance is a major problem that complicates disease management in patients with PHN \[[@CR40]\], and combination of G-GR effect on both pain and sleep disturbance may have a better effect on patient function itself. Consistent with this idea, for the overall effect of the G-GR treatment, similar percentages of elderly and younger patients reported feeling "Much" or "Very much" improved (14.4 vs. 11.3 %, respectively) when compared with placebo.

The safety profile of G-GR established in two phase III clinical trials in patients with PHN generally extended to the subgroup of patients ≥75 years, supporting the notion that tolerability of G-GR is not affected by age of the patient. In previous integrated analyses of phase III clinical trials, dizziness, somnolence, headache, and peripheral edema were the most commonly reported AEs for the entire study population receiving G-GR (*n* = 359), and a subgroup analysis revealed a slightly higher incidence of peripheral edema in patients ≥65 years (5.3 %) compared with patients aged ≤65 years of age (1.5 %) \[[@CR26]\]. In the current subgroup analysis of AEs by age, the most common AEs reported by patients aged ≥75 years included dizziness and somnolence, but also nausea, and the rates of occurrence were similar to those for patients aged \<75 years. The analysis revealed a similar occurrence of peripheral edema between patients ≥75 and \<75 years, whereas diarrhea was reported more often and headache less often by patients ≥75 years. Furthermore, all AEs associated with G-GR, including the most commonly reported AEs for gabapentinoids (dizziness and somnolence), decreased rapidly to sustained low levels after 3--5 weeks of treatment for all patients, regardless of their age. Finally, the rate of study discontinuation due to AEs for the G-GR group was very similar for older and younger patients (\~9.5 %).

Although no direct comparisons have been made between G-GR and gabapentin tid, the incidences of the most common gabapentinoid-related AEs (dizziness and somnolence) are lower for patients receiving G-GR. A placebo-controlled trial of gabapentin tid that used 1,800 or 2,400 mg/day \[[@CR41]\], or up to 3,600 mg/day \[[@CR42]\], reported rates of dizziness from 24 to 33 %, and rates of somnolence from 17 to 27 %. In contrast, G-GR rates of dizziness and somnolence reported for patients ≥75 years of age were 12 and 5 %, respectively. Better tolerability of the gastroretentive formulation may be due to more gradual elevation in serum levels of gabapentin compared with the immediate-release formulation. It could also result in part from the G-GR treatment regimen (once daily with the evening meal), when peak gabapentin concentrations occur during the period when most patients are asleep.

Limitations of this study include the short duration of stable gabapentin treatment (8 weeks), which allowed only short-term assessments of safety and efficacy, and the exclusion of patients with PHN who had either previously not responded to gabapentin or pregabalin, or had dose-limiting adverse effects preventing titration of gabapentin to an effective dose. Although these exclusion criteria may have resulted in an enriched patient population, this is how all clinical studies of gabapentin have been conducted, as it was not considered ethical to treat patients with a drug they could not tolerate or that did not provide therapeutic benefit.

Conclusion {#Sec14}
==========

The complexity of medical conditions and the use of medications to treat those conditions increase with age, providing the potential for drug interaction and more bothersome AEs that impact the patient's quality of life. Once-daily G-GR (1,800 mg with the evening meal) reduced pain from PHN, and improved sleep and overall quality of life for elderly patients with PHN (aged ≥75 years) to the same levels as for younger patients (aged \<75 years). The occurrence and patterns of AEs in the elderly were also comparable to those in younger patients, without increased risks for common AEs and with no additional safety signals. These results support the notion that both the drug efficacy and the relative risks for the commonly observed AEs with G-GR are not affected by increasing age or decreasing renal function. The clinically meaningful reductions in pain, coupled with the favorable tolerability profile of G-GR, its lack of significant interactions with other drugs, its convenient dosing, and ease of rapid titration to an efficacious dosage, make G-GR a valuable addition to PHN treatment in elderly patients.
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